FAB- GT Open-Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment -Naive Subjects With Classic Fabry Disease
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a multinational, open-label study to assess the efficacy and safety of AVR-RD-01 in
approximately 8 to 12 male subjects 16 years of age or older (18 years of age or older in the
US) and postpubertal with a confirmed diagnosis of classic Fabry disease based on deficient
AGA enzyme activity who have not previously received treatment with enzyme replacement
therapy (ERT) and/or chaperone therapy within 3 years of the time of Screening.